Opinion|Videos|March 11, 2025
Quality of Life and Patient Outcomes in mCRC Treatment
Experts discuss practical strategies used by their institutions to manage treatment-related toxicities with third-line therapies for metastatic colorectal cancer (mCRC) and share their experiences on how third-line therapy options have impacted patients’ quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What practical strategies does your institution use to manage treatment-related toxicities with third-line therapies for mCRC?
- In your experience, how have the third-line therapy options impacted your patients’ quality of life?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5